Schizophrenia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Schizophrenia is a chronic, severe, and disabling brain disease. The symptoms of schizophrenia may leave afflicted persons fearful and withdrawn. Their speech and behavior can become so disorganized that they are incomprehensible or frightening to others. Available treatments can relieve many schizophrenic symptoms, but most people with schizophrenia continue to suffer some symptoms throughout their lives; it has been estimated that no more than one in five individuals recovers completely. schizophrenic disorders have a multifactorial etiology, with genetic, environmental, and neurotransmitter pathophysiological components. At present, there is no laboratory method that confirms a diagnosis of schizophrenia. There may or may not be a history of a major disruption in the person's life (failure, loss, physical illness) before gross psychotic deterioration is evident.
·
The annual incidence of Schizophrenia varies
between 11 to 25 cases per every 100,000 population in the USA.
Thelansis’s “Schizophrenia Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Schizophrenia
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Schizophrenia across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Schizophrenia Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment